Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 versus physician's choice chemotherapy in previously treated advanced urothelial carcinoma
CTR20250662Phase 3Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Apr 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of izalontamab brengitecan in transitional cell carcinoma (TCC), sponsored by Biokin Pharmaceutical. Started Apr 2025; status: active.
02
Drugs
izalontamab brengitecan
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20250662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250662.